Efficient long‐term depletion of CD20+ B cells by rituximab does not affect gut‐resident plasma cells

B cell populations. Thus, we contend that, despite the results of the Rituximab study, there is a need for more intensive B cell-oriented research in inflammatory disorders, including IBD.